ZA200203120B - A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide T. - Google Patents
A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide T. Download PDFInfo
- Publication number
- ZA200203120B ZA200203120B ZA200203120A ZA200203120A ZA200203120B ZA 200203120 B ZA200203120 B ZA 200203120B ZA 200203120 A ZA200203120 A ZA 200203120A ZA 200203120 A ZA200203120 A ZA 200203120A ZA 200203120 B ZA200203120 B ZA 200203120B
- Authority
- ZA
- South Africa
- Prior art keywords
- thr
- peptide
- tyr
- asn
- ser
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title claims description 108
- 238000000034 method Methods 0.000 title claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 23
- 230000003612 virological effect Effects 0.000 title claims description 13
- 201000010099 disease Diseases 0.000 title claims description 12
- 108010071384 Peptide T Proteins 0.000 title description 68
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 31
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 31
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 claims description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 108700002232 Immediate-Early Genes Proteins 0.000 claims description 20
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 101150000195 EGR3 gene Proteins 0.000 claims description 16
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 230000002123 temporal effect Effects 0.000 claims description 8
- 230000029812 viral genome replication Effects 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- KVPFYRAFNZKJSD-CPXLMRBJSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CC1=CC=C(O)C=C1 KVPFYRAFNZKJSD-CPXLMRBJSA-N 0.000 claims description 5
- 150000008574 D-amino acids Chemical class 0.000 claims description 5
- 108010076464 peptide T amide Proteins 0.000 claims description 5
- IWHCAJPPWOMXNW-ZESMOPTKSA-N (2s,3r)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-2-[[(2r)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]-4-oxobutanoyl]amino]-3-(4-hydroxyphenyl)pr Chemical compound C[C@@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)CC1=CC=C(O)C=C1 IWHCAJPPWOMXNW-ZESMOPTKSA-N 0.000 claims description 4
- 230000037361 pathway Effects 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 230000002276 neurotropic effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 76
- 108090000623 proteins and genes Proteins 0.000 description 29
- 241000701460 JC polyomavirus Species 0.000 description 25
- 108091023040 Transcription factor Proteins 0.000 description 13
- 102000040945 Transcription factor Human genes 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 239000003623 enhancer Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000003900 neurotrophic factor Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 101100279531 Drosophila melanogaster egr gene Proteins 0.000 description 7
- 101100444902 Xenopus tropicalis egr1 gene Proteins 0.000 description 7
- 230000036755 cellular response Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004498 neuroglial cell Anatomy 0.000 description 7
- 230000003827 upregulation Effects 0.000 description 7
- 206010023163 JC virus infection Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 230000004075 alteration Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000002955 immunomodulating agent Substances 0.000 description 5
- 229940121354 immunomodulator Drugs 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 3
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 3
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000009456 molecular mechanism Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 101710151321 Melanostatin Proteins 0.000 description 2
- 102400000064 Neuropeptide Y Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002644 neurohormonal effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 1
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100445499 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erg-1 gene Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000712 neurohormone Substances 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000003363 transsynaptic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16436399P | 1999-11-09 | 1999-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200203120B true ZA200203120B (en) | 2002-11-27 |
Family
ID=22594146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200203120A ZA200203120B (en) | 1999-11-09 | 2002-04-19 | A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide T. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1242109A4 (de) |
JP (1) | JP2003528817A (de) |
KR (1) | KR20020063182A (de) |
CN (1) | CN1635913A (de) |
AU (1) | AU3080001A (de) |
CA (1) | CA2389392A1 (de) |
IL (1) | IL149443A0 (de) |
MX (1) | MXPA02004619A (de) |
WO (1) | WO2001034095A2 (de) |
ZA (1) | ZA200203120B (de) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6242564B1 (en) * | 1986-06-03 | 2001-06-05 | Candace B. Pert | Treatment of tropical spastic paresis with peptide T |
EP0635027B1 (de) * | 1992-03-27 | 2000-07-12 | Advanced Immunit T,Inc. | T-peptid und damit verwandte peptide in der behandlung von entzündungen einschliesslich der multiplen sklerose |
-
2000
- 2000-11-09 KR KR1020027006014A patent/KR20020063182A/ko not_active Application Discontinuation
- 2000-11-09 EP EP00990995A patent/EP1242109A4/de not_active Withdrawn
- 2000-11-09 IL IL14944300A patent/IL149443A0/xx unknown
- 2000-11-09 AU AU30800/01A patent/AU3080001A/en not_active Abandoned
- 2000-11-09 JP JP2001536100A patent/JP2003528817A/ja active Pending
- 2000-11-09 CA CA002389392A patent/CA2389392A1/en not_active Abandoned
- 2000-11-09 WO PCT/US2000/042030 patent/WO2001034095A2/en not_active Application Discontinuation
- 2000-11-09 CN CNA008154821A patent/CN1635913A/zh active Pending
- 2000-11-09 MX MXPA02004619A patent/MXPA02004619A/es unknown
-
2002
- 2002-04-19 ZA ZA200203120A patent/ZA200203120B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU3080001A (en) | 2001-06-06 |
MXPA02004619A (es) | 2004-09-10 |
WO2001034095A8 (en) | 2001-11-29 |
KR20020063182A (ko) | 2002-08-01 |
EP1242109A4 (de) | 2004-06-02 |
CN1635913A (zh) | 2005-07-06 |
EP1242109A2 (de) | 2002-09-25 |
JP2003528817A (ja) | 2003-09-30 |
WO2001034095A2 (en) | 2001-05-17 |
IL149443A0 (en) | 2002-11-10 |
CA2389392A1 (en) | 2001-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Herdegen et al. | Expression of JUN, KROX, and CREB transcription factors in goldfish and rat retinal ganglion cells following optic nerve lesion is related to axonal sprouting | |
Lewis et al. | Insulin-like growth factor-I: potential for treatment of motor neuronal disorders | |
Dubner et al. | Activity-dependent neuronal plasticity following tissue injury and inflammation | |
JP4067127B2 (ja) | 肥満症の処置のためのcntf(毛様体神経成長因子)受容体アクティベーターの使用 | |
Mocchetti et al. | Glucocorticoids differentially increase nerve growth factor and basic fibroblast growth factor expression in the rat brain | |
Glorioso et al. | Herpes vector-mediated gene transfer in treatment of diseases of the nervous system | |
Ganea et al. | Neuropeptides as modulators of macrophage functions. Regulation of cytokine production and antigen presentation by VIP and PACAP | |
CA2137916A1 (en) | Des-tyr dynorphin analogues | |
Dobrzynski et al. | Adenovirus-mediated kallikrein gene delivery attenuates hypertension and protects against renal injury in deoxycorticosterone-salt rats | |
Foreman et al. | Nerve growth factor and p75NGFR factor receptor mRNA change in rodent CNS following stress activation of the hypothalamo‐pituitary‐adrenocortical axis | |
KR20080098488A (ko) | Hiv 치료 | |
JPH06507386A (ja) | 治療用ペプチド | |
EP1002542B1 (de) | Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren | |
Liuzzi et al. | Effects of short-term estrogen replacement on trkA mRNA levels in axotomized dorsal root ganglion neurons | |
Giovannoni et al. | Multiple sclerosis and its treatment | |
JP7163547B2 (ja) | 新規ペプチドおよびその用途 | |
ZA200203120B (en) | A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide T. | |
US5534495A (en) | Treatment of non-HIV neuropathic pain syndromes | |
Rodriguez-Membrilla et al. | Endogenous CCK disrupts the MMC pattern via capsaicin-sensitive vagal afferent fibers in the rat | |
Mata et al. | Development of HSV-mediated gene transfer for the treatment of chronic pain | |
KR20150124941A (ko) | 골 계통 질환 치료약 및 그 용도 | |
JP2002510641A (ja) | 神経退化疾患治療用短ペプチド | |
EP0929671A1 (de) | Verfahren zur behandlung von amylotropher lateralsklerose | |
Hughes et al. | Neurotrophic factors and the development of drugs to promote motoneuron survival | |
CN117257950A (zh) | 一种预防带状疱疹复发的分子Prmt6的作用、实施方法及用途 |